NDA 020862 · Sanofi
Hectorol
Doxercalciferol · Oral
NovelDiscontinuedLast checked: Nov 19, 2026Latest source record: Jun 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Jun 9, 1999
Approved uses
3
Original approval plus efficacy supplements
Registered trials
23
3 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 11, 2025 Supplement 33 · Efficacy LetterLabel
- Apr 23, 2004 Supplement 6 · Efficacy LetterLabel
- Jun 9, 1999 Original approval · Type 1 - New Molecular Entity ReviewLetterLabel
3 products under this application
- HECTOROL · DOXERCALCIFEROL 2.5MCG · CAPSULE, ORAL · Discontinued · TE AB
- HECTOROL · DOXERCALCIFEROL 0.5MCG · CAPSULE, ORAL · Discontinued · TE AB
- HECTOROL · DOXERCALCIFEROL 1MCG · CAPSULE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Doxercalciferol" as an intervention, any sponsor and status, largest first.
- Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing HemodialysisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01181531 · 312 participants · Start Oct 1, 2010 · Primary completion Jul 17, 2012
Drug: Traditional Vitamin D Therapy; Cinacalcet · For: Hyperparathyroidism, Secondary
- Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002Pivotal-lookingCompleted
OPKO Health, Inc.Industry
NCT02282813 · 298 participants · Start Apr 2013 · Primary completion May 2015
Drug: CTAP101 Capsules; Calcitriol and 2 more · For: Chronic Kidney Disease; Hyperparathyroidism, Secondary; Vitamin D Deficiency
- Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin DPivotal-lookingCompleted
AbbottIndustry
NCT00977080 · 272 participants · Start Nov 2009 · Primary completion May 2011
Drug: Paricalcitol; Cinacalcet · For: Chronic Kidney Disease; Secondary Hyperparathyroidism; Hemodialysis
Sites: Tempe, Arizona; Chula Vista, California; Los Angeles, California · 83 sites in all
- ACHIEVE: Optimizing the Treatment of Secondary HyperparathyroidismPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00135304 · 170 participants · Start Aug 2005 · Primary completion Oct 2006
Drug: Sensipar®; Vitamin D · For: Secondary Hyperparathyroidism
- A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe PsoriasisPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00601107 · 111 participants · Start Apr 2008 · Primary completion Feb 2009
Drug: Doxercalciferol; Placebo · For: Moderate to Severe Chronic Plaque Psoriasis
Sites: Birmingham, Alabama; Hot Springs, Arizona; Little Rock, Arkansas · 19 sites in all
- Comparative Effects of Doxercalciferol and Calcitriol on Secondary Hyperparathyroidism in ESRDNot yet recruiting
Chittagong Medical CollegeAcademic, hospital or other
NCT07640347 · 98 participants (planned) · Start Jul 5, 2026 · Primary completion May 30, 2027
Drug: Doxercalciferol administration; oral calcitriol 0.25 microgram · For: Lowering Parathyroid Hormone Level in Patients on Hemodioalysis
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00123461 · 70 participants (planned) · Start Jul 2005 · Primary completion Oct 2007
Drug: Hectorol (doxercalciferol capsules), 0.5mcg · For: Secondary Hyperparathyroidism; Renal Failure; Chronic Renal Insufficiency
Sites: Phoenix, Arizona; Alhambra, California; Riverside, California · 19 sites in all
University of Wisconsin, MadisonAcademic, hospital or other
NCT00582582 · 70 participants · Start Apr 2002
Drug: Docetaxel plus doxercalciferol; Docetaxel plus placebo · For: Prostate Cancer
Sites: Madison, Wisconsin
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.
Petrich A, Kahl B, Bailey H, et al. · Leuk Lymphoma 2008 · Clinical Trial, Phase II
- Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol.
Kant KS, Gonzalez AR, Hariachar S, et al. · J Ren Nutr 2012 · Multicenter Study, Randomized Controlled Trial
- Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.
Zisman AL, Ghantous W, Schinleber P, et al. · Am J Nephrol 2005 · Clinical Trial, Phase IV, Comparative Study
- Vitamin D compounds for people with chronic kidney disease requiring dialysis.
Palmer SC, McGregor DO, Craig JC, et al. · Cochrane Database Syst Rev 2009 · Meta-Analysis, Systematic Review
- Efficacy and safety of doxercalciferol (1α hydroxyvitamin D2) on spine and femur bone mineral density in postmenopausal osteopenic women.
Gallagher JC, Mazess R · Front Endocrinol (Lausanne) 2026 · Randomized Controlled Trial, Clinical Trial
- Vitamin D compounds for people with chronic kidney disease not requiring dialysis.
Palmer SC, McGregor DO, Craig JC, et al. · Cochrane Database Syst Rev 2009 · Meta-Analysis, Systematic Review
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.